Skip to main content

Currently Skimming:

3 Results
Pages 19-42

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 19...
... The results are intended to support decision making about the sufficiency of evidence on new nutrient outcome relationships or other related criteria to support a comprehensive systematic review to update DRI nutrients in the United States and Canada. Key steps were to (1)
From page 20...
... Excluded Studies During screening, the committee removed articles for any reason identified in the prespecified exclusion criteria; however, it notes that many of these had more than one disqualifying reason. Table 3-1 shows the number of excluded articles by reason.
From page 21...
... Tables 3-2 and 3-3 provide descriptions of studies included for adequacy and chronic disease outcomes, respectively, including a notation of the outcome category identified in the analytic framework to which each relates (see Chapter 2, Figure 2-1) : adequacy (N = 24)
From page 22...
... * feeding 6 weeks (3 diet adjusted for 6 weeks individually for trial 12 women aged weeks short for riboflavin (2 weeks riboflavin intake and 19–27 years; and 3 weeks per calorie acclimatizati EGRAC excluded long intake ratio on and 2 × 2 individuals with exercise)
From page 23...
... for 5 mg/1,000 hour riboflavin intake can feeding aged 22–39 years; weeks kcal collections) be calculated based on trial excluded consumed)
From page 24...
... 7, and 11; Some participants no placebo had very low socioeconomic status Study 2: A subset of riboflavin deficient participants (N = 9) were also enrolled in a riboflavin supplementation study Boisvert et Controlled Guatemala Incremental Controlled EGRAC 0.65–0.70 EGRAC and urinary al.
From page 25...
... and a to 108 months; Contents of supplements correlation coefficient recruited at a well- supplements child clinic collected Supplement from labels use based on intake data, not an intervention.
From page 26...
... ; of riboflavin status EGRAC (method not reported) Jungert et al.
From page 27...
... reports sectional Study 1: 92 free- intake by one some intake and living adults aged assessment trained EGRAC response data Study 2: 65–91 years; nutritionist nested excluded Study 2: 1.6 through Study 2 (double-blind double- individuals who or 25 interview in randomized controlled blind, scored low on a mg/day trial) showed that 25
From page 28...
... (2002) d riboflavin biomarker data controlled 52 healthy adults supplement trial aged ≥60 years versus with sub-optimal placebo for riboflavin status 12 weeks (EGRAC ≥1.20)
From page 29...
... d riboflavin or diary hemoglobin increased controlled 117 healthy women placebo for in the intervention trial aged 19–25 years 8 weeks arm, suggesting a role with moderately of riboflavin with iron low riboflavin metabolism status (EGRAC value >1.40) ; excluded individuals who had pre-existing hematologic
From page 30...
... (1979) study qualitative between-subject 23 relatively record kept change in riboflavin healthy adults aged of all food intake and EGRAC 72–86 years; and drink over time; not a strong followed for 60 consumed for correlation between weeks 1 year and 1 EGRAC and intake day of food weighing every 6–8 weeks; a record of vitamin supplements containing riboflavin kept, and the contribution they made to the mean daily intake added to the dietary intake
From page 31...
... receiving prescribed supplements; included individuals who self-chose to take prenatal supplements; accounted for supplement use and riboflavin content in dietary intake data
From page 32...
... (2011) sectional report and corresponding study 120 adults aged EGRAC values 22–25 years; Intake from excluded supplements individuals with not assessed hemolytic anemia, lower activity of glucose-6 phosphate
From page 33...
... d riboflavin or improved controlled 42 adults aged 60– placebo for homocysteine and trial 94 years with low 28 days EGRAC but not riboflavin status ferritin, uric acid, or (EGRAC 1.2) ; C-reactive protein excluded individuals with hematological disorders; gastrointestinal, cardiovascular, hepatic or renal disease; impaired cognitive function; or taking B-vitamin supplements or drugs that affect riboflavin metabolism Tremblay et Randomize Canada 60 mg/day Dietary EGRAC Placebo No dietary data or al.
From page 34...
... . NOTE: EGRAC = Erythrocyte glutathione reductase activity/activation coefficient; EKG = electrocardiogram; HPLC = high-performance liquid chromatography; kcal = kilocalorie; max VO2 = maximal oxygen consumption; mg = milligram; N/A = not applicable; pmol = picomole; µmol/l = micromole/liter.
From page 35...
... study 24-hour compared to characterization of 12,245 adults aged ≥18 dietary baseline and riboflavin intake to years (mean 41.2 years) ; recalls quartiles of systolic and diastolic BP excluded pregnant combined intake as well as hypertension women and individuals with onset (intake–outcome with hypertension at household association)
From page 36...
... sectional Republic of Ireland validated for foods, fortified foods, cohort collection of and supplement use on 5,186 community- B vitamins; EGRAC and depression dwelling adults aged ≥60 included and anxiety years; excluded intake from individuals with supplements diagnosis of dementia or and fortified receiving vitamin B12 foods injections Rooney et al. Randomized United Kingdom 1.6 mg/day None EGRAC Placebo 1.6 mg/day riboflavin (2020)
From page 37...
... sectional Republic of Ireland information effect of riboflavin status cohort study (including on blood pressure in 6,076 adults aged 18– vitamin individuals with the 102 years recruited from supplement MTHFR C677 TT two national cohorts use) collected genotype; however, no for cohort dietary intake data for participants, riboflavin included but methods not reported Wilson et al.
From page 38...
... but not diastolic with the MTHFR 677TT 16 weeks blood pressure genotype; mean age of 69 years Excluded individuals with a history of gastrointestinal, hepatic, renal, or hematological disorders or taking B vitamin supplements, anticonvulsant therapy, or any other drugs known to interfere with folate or B-vitamin metabolism * Study cited in 1998 DRI report (IOM, 1998)
From page 39...
... , comparators, outcomes, and study designs.
From page 40...
... 1984. Relation of riboflavin nutriture in healthy elderly to intake of calcium and vitamin supplements: Evidence against riboflavin supplementation.
From page 41...
... 2002. Effect of riboflavin supplementation on plasma homocysteine in elderly people with low riboflavin status.
From page 42...
... 2013. Blood pressure in treated hypertensive individuals with the MTHFR 677TT genotype is responsive to intervention with riboflavin: Findings of a targeted randomized trial.


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.